Compare QH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | INAB |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 11.8M |
| IPO Year | 2019 | 2020 |
| Metric | QH | INAB |
|---|---|---|
| Price | $3.98 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 4.3K | ★ 36.9K |
| Earning Date | 04-02-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.88 |
| 52 Week High | $12.81 | $2.73 |
| Indicator | QH | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 44.87 |
| Support Level | $3.94 | $0.96 |
| Resistance Level | $4.41 | $1.22 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 16.00 | 39.42 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.